Application 075141
- Type
- ANDA
- Sponsor
- GALT PHARMS
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | ORPHENGESIC | ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE | TABLET;ORAL | 385MG;30MG;25MG | No | No |
| 002 | ORPHENGESIC FORTE | ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE | TABLET;ORAL | 770MG;60MG;50MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A075141-001 | ORPHENGESIC | ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | ||
| A075141-002 | ORPHENGESIC FORTE | ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | 74a2ff9319b5… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | AB | 1998-05-29 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | bb7c543d1eb4… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | 782e0a99824c… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | 87673890dc5c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | 5aa47cf7b7d7… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | 8869cabd3fbd… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | c0c555d07b60… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | 3f01610625f2… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | AB | 1998-05-29 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | b00525d2431f… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | AB | 1998-05-29 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | ea99ee380514… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | AB | 1998-05-29 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | 6a51e52b5d6a… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | 1c564ffb4f44… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | ea1830bbd6c7… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | a72a2bbeb626… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | 9b2671bbb829… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | a67488948f0b… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | 3f0d92c62455… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | 053a50430f4f… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | 3bdfa0b2c4d7… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A075141-001 | ORPHENGESIC | 385MG;30MG;25MG | TABLET / ORAL | 1998-05-29 | 3a93d1ddd44b… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A075141-002 | ORPHENGESIC FORTE | 770MG;60MG;50MG | TABLET / ORAL | RS | 1998-05-29 | 3a93d1ddd44b… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | A075141-002 | AB | 1 | 74a2ff9319b5… |
| 2019-12-14 00:12 UTC | 2019-12 | A075141-002 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A075141-002 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A075141-002 | AB | 1 | ea99ee380514… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Norgesic | ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE | Galt Pharmaceuticals, LLC | be2761bc-e537-4039-846a-2ffa3d8b2afc | 2026-01-08 | Warnings, Adverse reactions | 075141 ANDA075141 61825-305 |
| Norgesic Forte | ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE | Poly Pharmaceuticals, Inc. | 85a3b808-b476-f2f0-e053-2a91aa0af21f | 2025-12-30 | Warnings, Adverse reactions | 075141 ANDA075141 50991-999 |
| Orphenadrine Citrate, Aspirin and Caffeine | ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE | Atland Pharmaceuticals, LLC | 7776aae6-3cbd-4aed-9aac-4bed80339e27 | 2025-10-17 | Warnings, Adverse reactions | 075141 ANDA075141 |
| ORPHENGESIC FORTE | ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE | Galt Pharmaceuticals, LLC | 5bc485db-9d96-4291-aaa3-2a96ebf3098a | 2025-10-16 | Warnings, Adverse reactions | 075141 ANDA075141 61825-302 |
| Orphenadrine Citrate, Aspirin and Caffeine | ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE | Atland Pharmaceuticals, LLC | 61ca2af1-081c-411c-90ce-ec6d9e3157b2 | 2025-10-16 | Warnings, Adverse reactions | 075141 ANDA075141 71993-304 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 50991-999 | Norgesic Forte | Orphenadrine Citrate, Aspirin and Caffeine | Poly Pharmaceuticals, Inc. | ANDA | Current |
| 50991-999 | Norgesic Forte | Orphenadrine Citrate, Aspirin and Caffeine | Poly Pharmaceuticals, Inc. | ANDA | Current |
| 50991-999 | Norgesic Forte | Orphenadrine Citrate, Aspirin and Caffeine | Poly Pharmaceuticals, Inc. | ANDA | Current |
| 50991-999 | Norgesic Forte | Orphenadrine Citrate, Aspirin and Caffeine | Poly Pharmaceuticals, Inc. | ANDA | Current |
| 61825-302 | ORPHENGESIC FORTE | Orphenadrine Citrate, Aspirin and Caffeine | Galt Pharmaceuticals, LLC | ANDA | Current |
| 61825-302 | ORPHENGESIC FORTE | Orphenadrine Citrate, Aspirin and Caffeine | Galt Pharmaceuticals, LLC | ANDA | Current |
| 61825-302 | ORPHENGESIC FORTE | Orphenadrine Citrate, Aspirin and Caffeine | Galt Pharmaceuticals, LLC | ANDA | Current |
| 61825-305 | Norgesic | Orphenadrine Citrate, Aspirin and Caffeine | Galt Pharmaceuticals, LLC | ANDA | Current |
| 61825-999 | Orphengesic Forte | Orphenadrine Citrate, Aspirin and Caffeine | Galt Pharmaceuticals, LLC | ANDA | Current |
| 61825-999 | Orphengesic Forte | Orphenadrine Citrate, Aspirin and Caffeine | Galt Pharmaceuticals, LLC | ANDA | Current |
| 71993-304 | Orphenadrine Citrate, Aspirin and Caffeine | Orphenadrine Citrate, Aspirin and Caffeine | Atland Pharmaceuticals, LLC | ANDA | Current |
| 71993-304 | Orphenadrine Citrate, Aspirin and Caffeine | Orphenadrine Citrate, Aspirin and Caffeine | Atland Pharmaceuticals, LLC | ANDA | Current |
| 71993-999 | Orphenadrine Citrate, Aspirin and Caffeine | Orphenadrine Citrate, Aspirin and Caffeine | Atland Pharmaceuticals, LLC | ANDA | Current |
| 71993-999 | Orphenadrine Citrate, Aspirin and Caffeine | Orphenadrine Citrate, Aspirin and Caffeine | Atland Pharmaceuticals, LLC | ANDA | Current |
| 74157-999 | Orphenadrine Citrate, Aspirin and Caffeine | orphenadrine citrate, aspirin and caffeine | INA Pharmaceutics, Inc | ANDA | Current |
| 74157-999 | Orphenadrine Citrate, Aspirin and Caffeine | orphenadrine citrate, aspirin and caffeine | INA Pharmaceutics, Inc | ANDA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 22431 | ORIG | 1998-05-29 |